Toleranzia’s tolerogens are highly flexible – the disease-specific proteins may be adapted to a variety of autoimmune diseases.
Apart from Toleranzia’s primary indication, myasthenia gravis, Toleranzia has evaluated its technology portfolio in three other indications – positive treatment effects have been achieved in relevant animal models of diabetes type 1, rheumatoid arthritis, and multiple sclerosis. This validates Toleranzia’s technology as a technology portfolio with broad application potential for the development of new therapies in autoimmune diseases.
Below is a table of the indications that Toleranzia works in.
|Autoimmune disease||Positive treatment results
in animal models
|Myasthenia gravis (MG)||Yes||Preclinical phase|
|Rheumatoid arthritis (RA)||Yes||Discovery phase|
|Multipele sclerosis (MS)||Yes||Discovery phase|
|Diabetes type 1 (T1D)||Yes||Discovery phase|